349 related articles for article (PubMed ID: 28756619)
21. Primary Prostatic Carcinoma With De Novo Diffuse Neuroendocrine Differentiation.
Galea LA; Mow C; Fine SW; Manohar P
Int J Surg Pathol; 2022 Apr; 30(2):232-236. PubMed ID: 34338584
[TBL] [Abstract][Full Text] [Related]
22. Neuronal Trans-Differentiation in Prostate Cancer Cells.
Farach A; Ding Y; Lee M; Creighton C; Delk NA; Ittmann M; Miles B; Rowley D; Farach-Carson MC; Ayala GE
Prostate; 2016 Oct; 76(14):1312-25. PubMed ID: 27403603
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder.
Bollito ER; Pacchioni D; Lopez-Beltran A; Volante M; Terrone C; Casetta G; Mari M; DePompa R; Cappia S; Papotti M
Anal Quant Cytol Histol; 2005 Aug; 27(4):218-24. PubMed ID: 16220833
[TBL] [Abstract][Full Text] [Related]
24. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma.
Grobholz R; Griebe M; Sauer CG; Michel MS; Trojan L; Bleyl U
Hum Pathol; 2005 May; 36(5):562-70. PubMed ID: 15948124
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study.
Hirano D; Jike T; Okada Y; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Yoshida T; Takimoto Y
Ultrastruct Pathol; 2005; 29(5):367-75. PubMed ID: 16257863
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary Carcinomas With Mucinous and Neuroendocrine Differentiation: Expanding the Spectrum of Amphicrine Carcinomas.
Weissferdt A
Am J Surg Pathol; 2018 Sep; 42(9):1246-1252. PubMed ID: 30001241
[TBL] [Abstract][Full Text] [Related]
28. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
29. Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study.
Oxley JD; Abbott CD; Gillatt DA; MacIver AG
Br J Urol; 1998 Jan; 81(1):109-15. PubMed ID: 9467486
[TBL] [Abstract][Full Text] [Related]
30. Fine-needle aspiration of metastatic prostatic neuroendocrine carcinomas: cytomorphologic and immunophenotypic features.
Cai G; Ramdall RB; Levine P; Yang GC
Diagn Cytopathol; 2008 Aug; 36(8):545-9. PubMed ID: 18618716
[TBL] [Abstract][Full Text] [Related]
31. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
32. [Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype].
Bonkhoff H; Fixemer T
Pathologe; 2005 Nov; 26(6):453-60. PubMed ID: 16195860
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
[TBL] [Abstract][Full Text] [Related]
34. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract][Full Text] [Related]
35. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
Roudier MP; True LD; Vessella RL; Higano CS
J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
[TBL] [Abstract][Full Text] [Related]
36. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
Nordin A; Wang W; Welén K; Damber JE
Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
[TBL] [Abstract][Full Text] [Related]
37. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker".
Abrahamsson PA; Falkmer S; Fält K; Grimelius L
Pathol Res Pract; 1989 Sep; 185(3):373-80. PubMed ID: 2813190
[TBL] [Abstract][Full Text] [Related]
38. Histopathological and Clinical Differences Between Primary Breast Carcinomas With Neuroendocrine Features and Primary Breast Carcinomas Mimicking Neuroendocrine Features.
Kelten Talu C; Savli TC; Huq GE; Leblebici C
Int J Surg Pathol; 2019 Oct; 27(7):744-752. PubMed ID: 31195855
[TBL] [Abstract][Full Text] [Related]
39. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
Simon RA; di Sant'Agnese PA; Huang LS; Xu H; Yao JL; Yang Q; Liang S; Liu J; Yu R; Cheng L; Oh WK; Palapattu GS; Wei J; Huang J
Hum Pathol; 2009 Feb; 40(2):252-8. PubMed ID: 18835619
[TBL] [Abstract][Full Text] [Related]
40. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract.
Helpap B
Cancer; 2002 Oct; 95(7):1415-20. PubMed ID: 12237909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]